177 related articles for article (PubMed ID: 18381420)
1. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.
Zhang S; Phelan CM; Zhang P; Rousseau F; Ghadirian P; Robidoux A; Foulkes W; Hamel N; McCready D; Trudeau M; Lynch H; Horsman D; De Matsuda ML; Aziz Z; Gomes M; Costa MM; Liede A; Poll A; Sun P; Narod SA
Cancer Res; 2008 Apr; 68(7):2154-7. PubMed ID: 18381420
[TBL] [Abstract][Full Text] [Related]
2. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.
Iniesta MD; Gorin MA; Chien LC; Thomas SM; Milliron KJ; Douglas JA; Merajver SD
Cancer Genet Cytogenet; 2010 Oct; 202(2):136-40. PubMed ID: 20875877
[TBL] [Abstract][Full Text] [Related]
3. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.
Rashid MU; Jakubowska A; Justenhoven C; Harth V; Pesch B; Baisch C; Pierl CB; Brüning T; Ko Y; Benner A; Wichmann HE; Brauch H; Hamann U;
Eur J Cancer; 2005 Dec; 41(18):2896-903. PubMed ID: 16239104
[TBL] [Abstract][Full Text] [Related]
4. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
[TBL] [Abstract][Full Text] [Related]
5. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
[TBL] [Abstract][Full Text] [Related]
6. CHEK2-positive breast cancers in young Polish women.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Kowalska E; Oszurek O; Narod SA; Lubinski J
Clin Cancer Res; 2006 Aug; 12(16):4832-5. PubMed ID: 16914568
[TBL] [Abstract][Full Text] [Related]
7. Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland.
Kwiatkowska E; Skasko E; Niwinska A; Wojciechowska-Lacka A; Rachtan J; Molong L; Nowakowska D; Konopka B; Janiec-Jankowska A; Paszko Z; Steffen J
Neoplasma; 2006; 53(4):305-8. PubMed ID: 16830057
[TBL] [Abstract][Full Text] [Related]
8. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic.
Kleibl Z; Novotny J; Bezdickova D; Malik R; Kleiblova P; Foretova L; Petruzelka L; Ilencikova D; Cinek P; Pohlreich P
Breast Cancer Res Treat; 2005 Mar; 90(2):165-7. PubMed ID: 15803363
[TBL] [Abstract][Full Text] [Related]
9. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
[TBL] [Abstract][Full Text] [Related]
10. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
[TBL] [Abstract][Full Text] [Related]
12. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of breast cancer associated with CHEK2*1100delC.
Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
[TBL] [Abstract][Full Text] [Related]
14. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
[TBL] [Abstract][Full Text] [Related]
15. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
Nagel JH; Peeters JK; Smid M; Sieuwerts AM; Wasielewski M; de Weerd V; Trapman-Jansen AM; van den Ouweland A; Brüggenwirth H; van I Jcken WF; Klijn JG; van der Spek PJ; Foekens JA; Martens JW; Schutte M; Meijers-Heijboer H
Breast Cancer Res Treat; 2012 Apr; 132(2):439-48. PubMed ID: 21614566
[TBL] [Abstract][Full Text] [Related]
17. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
Wasielewski M; Vasen H; Wijnen J; Hooning M; Dooijes D; Tops C; Klijn JG; Meijers-Heijboer H; Schutte M
Clin Cancer Res; 2008 Aug; 14(15):4989-94. PubMed ID: 18676774
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention.
Cybulski C; Huzarski T; Byrski T; Gronwald J; Debniak T; Jakubowska A; Górski B; Wokołorczyk D; Masojć B; Narod SA; Lubiński J
Clin Genet; 2009 Jan; 75(1):72-8. PubMed ID: 19021634
[TBL] [Abstract][Full Text] [Related]
19. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
[TBL] [Abstract][Full Text] [Related]
20. No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors.
de Jong MM; Nolte IM; Te Meerman GJ; van der Graaf WT; Oosterom E; Bruinenberg M; Steege Gv; Oosterwijk JC; van der Hout AH; Boezen HM; Schaapveld M; Kleibeuker JH; de Vries EG
Eur J Cancer; 2005 Aug; 41(12):1819-23. PubMed ID: 16043347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
